Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 931 to 945 of 1455 results for do not do recommendations

  1. Molecular testing strategies for Lynch syndrome in people with colorectal cancer (DG27)

    Evidence-based recommendations on using immunohistochemistry or microsatellite instability testing to guide further testing for Lynch syndrome in people with colorectal cancer

  2. Guide to the methods of technology appraisal 2013 (PMG9)

    Guide to the methods of technology appraisal 2013

  3. What is the most clinically and cost-effective pathway for diagnosing clinically significant prostate cancer?

    Recommendation ID NG131/4 Question What is the most clinically and cost-effective pathway for diagnosing clinically significant prostate

  4. Good practice in safeguarding training

    A quick guide to good practice in safeguarding training

  5. Adapting NICE guidelines

    Our experts can offer advice and support in contextualising our guidelines, or helping you adapt our content to your country or local context.

  6. Brentuximab vedotin in combination for untreated systemic anaplastic large cell lymphoma (TA641)

    Evidence-based recommendations on brentuximab vedotin (Adcetris) with cyclophosphamide, doxorubicin and prednisone for untreated systemic anaplastic large cell lymphoma in adults.

  7. What is the natural history of people with a Likert score on MRI of less than 3 without biopsy at long-term follow‑up?

    Recommendation ID NG131/5 Question What is the natural history of people with a Likert score on MRI of less than 3 without biopsy at...

  8. What is the most clinically and cost-effective pathway for diagnosing clinically significant prostate cancer?

    Recommendation ID NG131/3 Question What is the most clinically and cost-effective pathway for diagnosing clinically significant prostate

  9. Apixaban for the treatment and secondary prevention of deep vein thrombosis and/or pulmonary embolism (TA341)

    Evidence-based recommendations on apixaban (Eliquis) for treating and preventing recurrent deep vein thrombosis or pulmonary embolism in adults.

  10. Targeted-release budesonide for treating primary IgA nephropathy (TA937)

    Evidence-based recommendations on targeted-release budesonide (Kinpeygo) for treating primary immunoglobulin A (IgA) nephropathy in adults.

  11. Heart failure algorithms for remote monitoring in people with cardiac implantable electronic devices (DG61)

    Evidence-based recommendations on CorVue (Abbott Medical), HeartInsight (Biotronik), HeartLogic (Boston Scientific) and TriageHF (Medtronic) for algorithm-based remote monitoring in people with cardiac implantable electronic devices

  12. What are the long-term outcomes of different management strategies for primary hyperparathyroidism? Which strategies are most cost effective?

    Recommendation ID NG132/3 Question What are the long-term outcomes of different management strategies for primary hyperparathyroidism?